Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin de Kort

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Drug Discovery Today|June 1, 2005
Synthetic heparin derivatives as new anticoagulant drugsMartin de Kort, Rogier C Buijsman, Constant A A van Boeckel
British Journal of Clinical Pharmacology|September 18, 2012
Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrier® insulinAndré M M Miltenburg, Marita Prohn, Jacqueline H M van Kuijk, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|April 17, 2003
A versatile approach towards regioselective platinated DNA sequencesRobert J Heetebrij, Martin de Kort, Nico J Meeuwenoord, et al.
Thrombosis and Haemostasis|November 6, 2009
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profileMaurice Petitou, Vanessa Nancy-Portebois, Guy Dubreucq, et al.
Chemmedchem|June 11, 2015
Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 DiabetesNigel Irwin, Steven Patterson, Martin de Kort, et al.
Frontiers in Medicine|February 1, 2024
Drug repurposing for rare: progress and opportunities for the rare disease communityAnneliene Hechtelt Jonker, Daniel O'Connor, Maria Cavaller-Bellaubi, et al.
Molecular Genetics and Metabolism|March 14, 2025
SIMPATHIC: Accelerating drug repurposing for rare diseases by exploiting SIMilarities in clinical and molecular PATHologyClara D M van Karnebeek, Annelieke R Müller, Laura Benkemoun, et al.
Nature Reviews. Drug Discovery|March 19, 2025
Computational drug repurposing: approaches, evaluation of in silico resources and case studiesZiaurrehman Tanoli, Adrià Fernández-Torras, Umut Onur Özcan, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Drug Discovery Today|June 1, 2005
Synthetic heparin derivatives as new anticoagulant drugsMartin de Kort, Rogier C Buijsman, Constant A A van Boeckel
British Journal of Clinical Pharmacology|September 18, 2012
Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrier® insulinAndré M M Miltenburg, Marita Prohn, Jacqueline H M van Kuijk, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|April 17, 2003
A versatile approach towards regioselective platinated DNA sequencesRobert J Heetebrij, Martin de Kort, Nico J Meeuwenoord, et al.
Thrombosis and Haemostasis|November 6, 2009
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profileMaurice Petitou, Vanessa Nancy-Portebois, Guy Dubreucq, et al.
Chemmedchem|June 11, 2015
Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 DiabetesNigel Irwin, Steven Patterson, Martin de Kort, et al.
Frontiers in Medicine|February 1, 2024
Drug repurposing for rare: progress and opportunities for the rare disease communityAnneliene Hechtelt Jonker, Daniel O'Connor, Maria Cavaller-Bellaubi, et al.
Molecular Genetics and Metabolism|March 14, 2025
SIMPATHIC: Accelerating drug repurposing for rare diseases by exploiting SIMilarities in clinical and molecular PATHologyClara D M van Karnebeek, Annelieke R Müller, Laura Benkemoun, et al.
Nature Reviews. Drug Discovery|March 19, 2025
Computational drug repurposing: approaches, evaluation of in silico resources and case studiesZiaurrehman Tanoli, Adrià Fernández-Torras, Umut Onur Özcan, et al.
Pageof 1